A drug which can remove toxic phosphorous in patients with chronic kidney failure has been developed by researchers at Indian Institute of Technology-Madras. The drug called Sevelamer Hcl has received a patent process.
Sevelamer Hcl is already marketed by Emcure Pharmaceuticals under the brand name Foseal. The drug is an oral medicine, which binds to the excessive phosphorus in the body and is excreted through feces. This novel drug was developed by organic chemist and IIT-M professor S Sankararaman along with Madras Institute of Nephrology (MIN).
"It was a project between doctors and engineers initiated under the socially relevant projects initiative of IIT-M. It was started in 2003 with the vision of being in a dynamic equilibrium with our social environment," IIT-M director MS Ananth told reporters. "In a country where the doctor-patient ratio is small and doctors have very little time for research, its vital for institutions like ours to collaborate."
When given early to kidney failure patients, the drug delays dialysis and increases longevity with better quality of life in patients who are on dialysis.